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PET Studies of Cerebral Levodopa 
Metabolism: A Review of Clinical 
Findings and Modeling Approaches
Yoshitaka Kumakura and Paul Cumming
certainly due to the formation of the AAADC product 
[18F]fluorodopamine and the trapping of this product in 
synaptic vesicles of nigrostriatal fibers. Thus, specific 
radiolabeling of dopamine neurons can be visualized at 
approximately 1 hour after FDOPA injection, when the 
maximum contrast between striatum and nonbinding 
reference regions occurs (Garnett and others 1983).
The ratio between striatum and cerebellum radio-
activity in an FDOPA study is a robust indicator of the 
integrity of the nigrostriatal dopamine pathway. However, 
the physiological interpretation of FDOPA-PET requires 
explicit pharmacokinetic models. There are a number of 
competing approaches for quantifying FDOPA-PET; 
model selection always entails a trade-off between real 
physiological complexity, and the simplicity and robust-
ness of the method. Diverse approaches to FDOPA 
modeling have been tested and compared (Hoshi and 
others 1993), and the clinical findings have been reviewed 
(Cumming and Gjedde 1998). The present review sum-
marizes the state of the art for analysis of FDOPA-PET, 
highlighting the advantages and disadvantages of the 
various methods. Some of the latest findings of preclini-
cal and clinical PET studies with FDOPA are presented, 
with an emphasis on applications for psychiatry, neurol-
ogy, and the study of human personality and cognition.
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The synthetic amino acid [
18F]fluoro-3,4-dihy-
droxyphenyl-l-alanine (FDOPA) was one of the 
first tracers available for molecular brain imag-
ing by positron emission tomography (PET). During 
the past 25 years, FDOPA, along with [11C]DOPA and 
some other radioactive substrates for aromatic amino 
acid decarboxylase (AAADC), has emerged as an invalu-
able agent for the investigation of the functional state 
of dopamine innervations in living brain. Dynamic 
FDOPA-PET recordings reveal a time-dependent distri-
bution of radioactivity in the brain in the hours after 
intravenous injection of the tracer. Whereas the initial 
influx of FDOPA to brain is spatially homogeneous, the 
radioactivity concentration within the healthy striatum 
soon surpasses that seen in other brain regions. This is 
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[18F]Fluoro-3,4-dihydroxyphenyl-l-alanine (FDOPA) was one 
of the first successful tracers for molecular imaging by posi-
tron emission tomography (PET), and has proven immensely 
valuable for studies of Parkinson’s disease. Following intrave-
nous FDOPA injection, the decarboxylated metabolite [18F]
fluorodopamine is formed and trapped within terminals of 
the nigrostriatal dopamine neurons; reduction in the simple 
ratio between striatum and cerebellum is indicative of nigros-
triatal degeneration. However, the kinetic analysis of dynamic 
FDOPA-PET recordings is formidably complex due to the 
entry into brain of the plasma metabolite O-methyl-FDOPA 
and due to the eventual washout of decarboxylated metabo-
lites. Linear graphical analysis relative to a reference tissue 
input function is popular and convenient for routine clinical 
studies in which serial arterial blood samples are unavailable. 
This simplified approach has facilitated longitudinal studies 
in large patient cohorts. Linear graphical analysis relative to 
the metabolite-corrected arterial FDOPA input yields a more 
physiological index of FDOPA utilization, the net blood-brain 
clearance. Using a constrained compartmental model, 
FDOPA-PET recordings can be used to calculate the relative 
activity of the enzyme DOPA decarboxylase in living brain. 
We have extended this approach so as to obtain an index of 
steady-state trapping of [18F]fluorodopamine in synaptic ves-
icles. Although simple methods of image analysis are suffi-
cient for the purposes of routine clinical studies, the more 
complex approaches have revealed hidden aspects of brain 
dopamine in personality, healthy aging, and in the pathophys-
iologies of Parkinson’s disease and schizophrenia.
Keywords: FDOPA; fluorodopa; PET; kinetic modeling; 
steady state; Parkinson’s disease; schizophrenia; aging
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General Aspects of the Kinetic 
Analysis of FDOPA Metabolism
PET recordings show the total radioactivity concentra-
tion in living tissue, irrespective of any biotransformation 
of the tracer. In the case of FDOPA-PET, the tracer 
enters into the pathway for dopamine synthesis (Fig. 1). 
Endogenous DOPA is normally synthesized in living 
brain by tyrosine hydroxylase. Consequently, FDOPA-
PET circumvents the classical rate-limiting step of 
Figure 1. The pathway for the synthesis and catabolism of dopamine. Abbreviations: PH = phenylalanine hydroxylase; BH2/BH4 = 
dihydo- and tetrahydrobiopterin;  TH = tyrosine hydroxylase; AAADC = aromatic amino acid decarboxylase; MAO = monoamine oxidase; 
COMT = catechol-O-methyltransferase; SAM = S-adenosylmethionine; 3MT = 3-methoxyryramine; DOPAC = dihydroxyphenylacetic acid; 
HVA = homovanillic acid. Figure courtesy of Dr. Svend Jensen, Aarhus University.
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catecholamine synthesis. Once entering striatum, 
FDOPA is decarboxylated by AAADC, yielding [18F]
fluorodopamine, which is retained for a time within 
dopamine vesicles, but is ultimately decomposed by the 
successive actions of monoamine oxidase (MAO) and 
catechol-O-methyltransferase (COMT). The resultant 
acidic metabolites, [18F]DOPAC and [18F]HVA (Cumming 
and others 1987), are free to diffuse out of brain.
Inasmuch as FDOPA is also a substrate for AAADC 
throughout the body, subjects for brain PET studies are 
generally pretreated with the peripherally acting AAADC 
inhibitor carbidopa. In this condition, plasma FDOPA is 
mainly metabolized by liver COMT. Within 30 minutes of 
FDOPA injection, the inert metabolite O-methyl-FDOPA 
(OMFD) is the major radioactive species in plasma of 
humans (Boyes and others 1986) and rats (Cumming and 
others 1987). The several approaches for the quantitation 
of cerebral FDOPA kinetics must somehow correct for the 
plasma-derived OMFD, which presents a homogeneous 
background radioactivity somewhat obscuring the signal 
related to [18F]fluorodopamine synthesis.
Other Substrates for PET 
Studies of AAADC
Although FDOPA and DOPA are not distinguished by 
AAADC in vitro (Cumming and others 1988), FDOPA 
is a better substrate for COMT than is natural DOPA, 
such that large amounts of the plasma metabolite 
OMFD are formed in vivo (Cumming and others 1995a). 
The alternate tracer β-[11C]DOPA is preferable for PET 
studies of AAADC metabolism, because it yields much 
less of the inert plasma metabolite (Torstenson and oth-
ers 1999). Furthermore, the shorter half-life of [11C] 
(20 min) relative to [18F] (110 min) might permit phar-
macological challenge studies, in which a subject is 
scanned twice in succession on the same PET scanning 
day. Unfortunately, the complex radioenzymatic synthe-
sis of β-[11C]DOPA seems to have discouraged its wide-
spread use. On the other hand, the [18F]-precursor or 
FDOPA itself can be shipped hundreds of kilometers 
from a cyclotron/radiochemistry facility.
The alternate AAADC substrate 6-[18F]-l-meta-
tyrosine (FMT) is not a substrate for COMT, and so 
does not yield a kinetically troublesome brain-penetrating 
metabolite. FMT rapidly enters brain and gives rise to 
a more intense labeling of striatum than is typical of 
FDOPA (Brown and others 1999). Influx plots of FMT 
or FDOPA were equally sensitive to the nigrostriatal 
degeneration in monkeys with MPTP-induced parkin-
sonism, although only FDOPA revealed clear evidence 
of the late washout phase related to breakdown of dop-
amine (Doudet and others 1999). Perplexingly, the 
decarboxylated product of FMT, 6-[18F]-meta-tyramine, 
is not sequestered in synaptic vesicles (Endres and oth-
ers 1997), but is instead rapidly metabolized by MAO, 
yielding the acidic metabolite [18F]hydroxyphenylacetic 
acid (Jordan and others 1998). In general, acidic metab-
olites should diffuse from brain, so it is unclear how the 
specific FMT signal is retained so effectively within liv-
ing striatum.
FDOPA: The “Worst Case” Scenario
FDOPA kinetic modeling is based upon the earlier expe-
rience with FDG, the tracer for PET studies of glu-
cose consumption (Phelps and others 1979). Whereas 
the model for analysis FDG-PET safely assumes irre-
versible trapping of the tracer in brain, the explicit 
FDOPA model is considerably more complex. Indeed, 
the kinetic modeling of FDOPA is a “worst case” sce-
nario, due to the entry of the plasma metabolite to brain, 
and due also to progressive violation of the assumption 
of irreversible trapping, that is, washout. In an explicit 
FDOPA model, each biochemical or physiological pro-
cess is expressed as a kinetic term, the definitions and 
abbreviations of which are listed in Table 1. In practice, 
it is necessary to reduce the complexity of the model, as 
illustrated in Figure 2A, which is essentially a simplifi-
cation of the more detailed models presented earlier 
(Huang and others 1991; Cumming and Gjedde 1998). 
Due to the nature of the dopamine pathway, an FDOPA-
PET recording lasting several hours reveals three dis-
tinct phases: 1) the initial tracer uptake across the 
blood-brain barrier, 2) the formation and trapping of 
[18F]fluorodopamine in dopamine vesicles, and 3) the 
late phase of washout of acidic metabolites.
Complete FDOPA kinetic modeling requires serial 
arterial blood samples, obtained from a catheter placed 
in a radial artery, to measure the total radioactivity con-
centration as a function of time after injection. This 
proportions of untransformed FDOPA and OMFD in 
plasma change continuously and must be separated. In 
the early days, the FDOPA and OMFD fractions were 
separated from blood plasma using powdered alumina 
(Boyes and others 1986), but this solid-phase method 
has been largely supplanted by HPLC (Cumming and 
others 1993). The end result is a pair of arterial inputs, 
one for the declining amounts of untransformed FDOPA 
and one for the increasing amounts of OMFD.
Gjedde-Patlak Linear Graphic 
Analysis Applied to FDOPA
When a “pure” FDOPA arterial input is available, 
FDOPA uptake in brain can be analyzed by a linear 
graphical analysis, derived from the method for calcu-
lating net flux of FDG to brain (Gjedde 1982; Patlak 
and others 1983). The troublesome plasma metabolite 
OMFD enters readily into the brain and soon becomes 
the predominant radioactive compound in most regions 
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of rat brain (Cumming and others 1987) and primate 
brain (Firnau and others 1987). To isolate the process 
of FDOPA trapping in brain, it is first necessary to sub-
tract by some means the brain radioactivity due to 
OMFD, which is generally assumed to be the sole 
labeled metabolite in reference regions, that is, the 
cerebellum or occipital cortex (Fig. 2B). Subtraction of 
the entire radioactivity in the reference region has been 
a convenient approximation for calculation of FDOPA 
influx in the presence of interference from OMFD 
(Martin and others 1989). Following this crude sub-
traction, the linear regression slope of the plot of 
FDOPA distribution volume (Ct(t)/Cp(t)) versus the 
normalized arterial FDOPA input (IntCp(t)/Cp(t)) is 
defined as the net blood-brain FDOPA clearance (Kin
app; 
mL g–1 min–1), an index of the capacity for dopamine 
synthesis in striatum.
Some representative results obtained using the linear 
graphic analysis in monkey and human are presented in 
Table 2. The magnitude of Kin
app is a sensitive indicator 
of nigrostriatal degeneration, although its physiological 
interpretation is subject to several caveats. In particu-
lar, Kin
app (Fig. 2) is a macroparameter comprised of the 
FDOPA diffusion across the blood-brain barrier and 
the rate of decarboxylation by brain AAADC. Inasmuch 
as the initial transfer to brain is sensitive to competi-
tion from other substrates for the common carrier of 
large neutral amino acids, FDOPA-PET subjects should 
be scanned in a fasting condition. The magnitude of 
Kin
app reveals the maximal capacity for synthesizing dop-
amine from DOPA arriving in blood, but does not indi-
cate the real rate of dopamine synthesis from DOPA 
formed in situ.
When, as is often the case, it is impractical to mea-
sure the arterial FDOPA input, an alternate index of 
FDOPA utilization can be calculated by linear graphic 
analysis relative to a reference tissue, assumed to be 
devoid of AAADC activity. The time activity curve 
(TAC) measured in a reference region (Fig. 3B) serves 
as a surrogate for the missing arterial FDOPA input for 
Table 1. Definitions of Abbreviations and Kinetic Terms Used in the Text
Term Units Definition
FDOPA  6-[18F]Fluoro-3,4,-dihydroxyphenyl-l-alanine
OMFD  O-Methyl-FDOPA
K1 mL g
–1 min–1 Unidirectional blood-brain clearance of a tracer across 
   blood-brain barrier, K1
D for FDOPA and K1
M for OMFD
k2 min
–1 Fractional rate constant for the diffusion of a tracer 
   from brain, k2
D for FDOPA, and k2
M for OMFD
Ve mL g
–1 The equilibrium distribution volume of a tracer in a nontrapping 
   region (K1
D/k2
D for FDOPA)
k3
D min–1 The relative activity of DOPA decarboxylase with respect to FDOPA, 
   calculated assuming irreversible trapping of decarboxylated metabolites 
   in brain, uncorrected for the loss, i.e., uncorrected for the real loss of  
   these metabolites
k3 min
–1 The relative activity of DOPA decarboxylase with respect 
   to FDOPA, inherently corrected for the loss of decarboxylated 
   metabolites from brain. (Identical to k3
D* in Cumming and others 2001)
k3
S (or Kocc) min–1 The utilization rate constant of FDOPA calculated by graphical 
   analysis using an (occipital cortex) reference tissue input
Kin
app mL g–1 min–1 The net unidirectional blood-brain clearance of FDOPA 
   in a region of interest calculated by graphical analysis, with subtraction 
   of the total radioactivity measured in a non-trapping region, and assuming 
   no elimination of decarboxylated metabolites. Identical to K1
D/(k2
D+ k3D).
K mL g–1 min–1 The intrinsic blood-brain clearance of a tracer defined kinetically 
   in terms of K1, k2 and k3. (Kumakura and others 2005) 
   Identical to K1
D/(k2
D+ k3).
kloss min
–1 The rate constant for the elimination of decarboxylated FDOPA metabolites  
   from brain (See: Holden and others 1997)
EDV mL g–1 The ratio K/kloss, an index of the steady-state storage of the metabolite 
   compartment in brain, following our previous definition of EDV2 (Kumakura 
   and others 2005, 2006; cf. EDV1).
V0 mL g
–1 Effective plasma volume
Vf mL g
–1 Distribution volume of precursor pool
Vd mL g
–1 Total distribution volume in brain tissue (= EDV + Vf + V0), 
   an index of the steady-state storage in brain
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Figure 2.  A schema describing the kinetic models of 6-[18F]fluoro-l-dopa (FDOPA). A, The distribution of FDOPA across the blood-brain 
barrier is mediated by the unidirectional clearance (K1
D; mL g–1 min–1), and the facilitated diffusion back to circulation (k2
D; min–1). FDOPA 
residing in the precursor pool is decarboxylated by aromatic amino acid decarboxylase (AAADC; k3
D; min–1) and is assumed to be irrevers-
ibly trapped. The net influx (Kin
app; mL g–1 min–1) is a macroparameter comprising the preceding processes. For the sake of clarity, 3-O-
methyl-[18F]FDOPA (OMFD) is not included in this schema, but is indicated in B. The contribution of OMFD to brain radioactivity must be 
removed by subtraction. C, The distribution volume of the tracer in a brain region is distributed into three compartments: intravascular 
space (Vo, mL g
–1), extravascular tissue (precursor pool, Vf, mL g
–1), and metabolite compartment (trapped tracer, EDV, mL g–1). Here, the 
AAADC activity is designated k3
D*, to indicate that it is corrected for loss of metabolites, as is the intrinsic blood-brain clearance of FDOPA 
(K, mL g–1 min–1). The AAADC product [18F]fluorodopamine formed in brain, together with its acidic metabolites, is assumed to diffuse from 
the brain as a single compartment (kloss, min
–1).
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calculating the rate of FDOPA decarboxylation, here 
defined as k3
S (min–1) (Bruck and others 2006; Hoshi 
and others 1993; Ishiwata and others 2007). This 
approach has proven eminently useful for clinical stud-
ies of Parkinson’s disease progression in large cohorts. 
Parametric maps (Fig. 4) show that the magnitude of 
k3
S is reduced more in the putamen than in the caudate 
of patients with Parkinson’s disease, consistent with 
post mortem findings.
There has been some confusion in terminology for 
the FDOPA reference tissue graphical analysis, which 
has been called k3
s, Ki,, K
occ, or Kref, all with units of 
min–1 (Patlak and Blasberg 1985; Hoshi and others 
1993). We prefer the term k3
s, inasmuch as capital K 
should properly be reserved for blood-brain clearances, 
which has units of mL g–1 min–1 (Gjedde 1982; Patlak 
and others 1983). Despite different assumptions, the 
magnitude of k3
s actually correlates well with those of 
Kin
app (see Fig. 4). Whatever it may be called, the slope 
of the reference tissue graphic analysis implicitly 
assumes that the fraction of FDOPA in the reference 
tissue remains constant over time (Hartvig and others 
1991), whereas it is known that within 30 minutes after 
FDOPA injection, OMFD becomes the predominant 
Table 2. Results of Some Quantitative Studies of FDOPA Metabolism in Striatum of Monkey and Human
Monkey
(Cumming and others 2001)  Caudate Putamen
Kin
app (mL g–1 min–1) Normal (n = 6) 0.0127 ± 0.0045 0.0123 ± 0.0043
 MPTP (n = 6) 0.0043 ± 0.0034 0.0041 ± 0.0027
k3
D (min–1) Normal 0.033 ± 0.010 0.035 ± 0.006
 MPTP 0.010 ± 0.007 0.009 ± 0.005
kloss (min
–1) Normal 0.0022 ± 0.0008 0.0016 ± 0.0003
 MPTP 0.0056 ± 0.0034 0.0054 ± 0.0030
Human
(Kumakura and others 2005)
Kin
app (mL g–1 min–1) Healthy young (n = 7) 0.0082 ± 0.0021 0.0124 ± 0.0023
 Healthy aged (n = 8) 0.0082 ± 0.0017 0.0135 ± 0.0018
K (mL g–1 min–1) Healthy young 0.0135 ± 0.0038 0.0180 ± 0.0034
 Healthy aged 0.0132 ± 0.0025 0.0196 ± 0.0024
kloss (min
–1) Healthy young 0.0013 ± 0.0008 0.0016 ± 0.0008
 Healthy aged 0.0035 ± 0.0017 0.0037 ± 0.0015
EDV (mL g–1) Healthy young 13.8 ± 7.2 14.2 ± 7.7
 Healthy aged 4.8 ± 2.8 6.0 ± 2.6
(Kumakura and others 2006) 
Kin
app (mL g–1 min–1) Healthy aged (n = 6) 0.0067 ± 0.0017 0.0111 ± 0.0012
 Parkinson’s disease (n = 8) 0.0040 ± 0.0031 0.0062 ± 0.0013
kloss (min
–1) Healthy aged 0.0052 ± 0.0018 0.0046 ± 0.0017
 Parkinson’s disease  0.0090 ± 0.0043 0.0114 ± 0.0034
EDV (mL g–1) Healthy aged  2.6 ± 1.3 4.1 ± 1.2
 Parkinson’s disease  1.6 ± 1.0 1.7 ± 0.5
(Kumakura and others 2007)
Kin
app (mL g–1 min–1) Healthy subjects (n = 15) 0.0081 ± 0.0018 0.0117 ± 0.0019
 Schizophrenia (n = 8) 0.0071 ± 0.0021 0.0126 ± 0.0019
K (mL g–1 min–1) Healthy subjects 0.0144 ± 0.0033 0.0181 ± 0.0036
 Schizophrenia 0.0175 ± 0.0028 0.0237 ± 0.0042
kloss (min
–1) Healthy subjects 0.0041 ± 0.0012 0.0037 ± 0.0015
 Schizophrenia 0.0080 ± 0.0038 0.0063 ± 0.0029
Vd (mL g
–1) Healthy subjects 4.0 ± 1.8 5.9 ± 2.7 
 Schizophrenia 2.5 ± 0.8 4.3 ± 1.1
Mean results are presented from the non-steady-state analyses assuming irreversible trapping of decarboxylated metabolites (k3
S = the DOPA decarboxylase activity 
relative to a reference tissue input; k3
D = the DOPA decarboxylase activity relative to the arterial input; Kinapp = the net blood-brain clearance) and for steady-state 
models (K = the net blood-brain clearance; kloss = the washout rate constant for [18F]dopamine; EDV = the steady-state storage effective for vesicular retention; Vd = 
the total steady-state storage for 6-[18F]fluoro-3,4,-dihydroxyphenyl-l-alanine [FDOPA] together with its decarboxylated metabolites). MPTP = neurotoxin-induced 
syndrome of acquired parkinsonism.
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source of radioactivity in the reference tissue. Conse-
quently, the magnitude of k3
s must underestimate the 
true AAADC activity in striatum, because the refer-
ence tissue TAC progressively overestimates the real 
precursor concentration. Researchers who demand 
more strict physiological measures of AAADC must 
resort to compartmental modeling, rather than graphi-
cal analysis.
Figure 3. 6-[18F]Fluoro-l-dopa (FDOPA) kinetics in blood and brain. A, The total time radioactivity curve in arterial plasma () and the 
concentration of FDOPA (). B, Representative time-activity curves in cerebellum and putamen of a patient with mild Parkinson’s disease, 
showing the effect of mathematical subtraction of the radioactivity due to 3-O-methyl-[18F]FDOPA. C, Reference tissue plots for the utiliza-
tion of FDOPA in putamen. D, Linear graphical analysis of FDOPA influx in putamen, showing that conventional subtraction of cerebellum 
radioactivity () results in underestimation of the true net influx. 
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The Three Compartments for FDOPA 
Pharmacokinetic Modeling
The objective of technically demanding compartmen-
tal modeling for FDOPA is to estimate the rate con-
stant for the formation of [18F]fluorodopamine in 
living brain, expressed as the AAADC enzyme activity 
rate constant k3
D (min–1). As such, FDOPA is one of the 
very few PET tracers for measuring the activity of an 
enzyme in living brain. According to the conventions of 
compartmental analysis, the total radioactivity concen-
tration in brain is distributed into three compartments: 
FDOPA in blood, FDOPA in the brain tissue (the pre-
cursor pool), and the metabolite compartment (trapped 
[18F]fluorodopamine), neglecting, for the sake of clarity, 
the background of OMFD (Fig. 2A). The common car-
rier for large neutral amino acids facilitates the diffu-
sion of plasma FDOPA to brain; this unidirectional 
blood-brain clearance (K1
D; mL g–1 min–1) is equal to the 
product of the extraction fraction of FDOPA multiplied 
by cerebral blood flow. The common carrier for large 
amino acids acts as a “revolving door,” such that brain 
FDOPA is cleared back to circulation (k2
D min–1). The 
net effect is that FDOPA, OMFD, and the endogenous 
large neutral amino acid substrates are all equilibrated 
across the blood-brain barrier, a concept that inspired 
the constrained approach for compartmental analysis 
of FDOPA in the presence of OMFD (Gjedde and oth-
ers 1991; Huang and others 1991). In this model, the 
number of free parameters describing the blood-brain 
Figure 4. Mean parametric maps of 6-[18F]fluoro-l-dopa (FDOPA) utilization and trapping in groups of patients with schizophrenia (SZ; 
n = 8), young healthy subjects (n = 14), aged healthy subjects (n = 14), and patients with Parkinson’s disease (PD; n = 8). Maps show the 
FDOPA utilization relative to a reference tissue input (k3
s), the conventional linear graphical analysis of FDOPA influx (Kin
app), and the steady-
state distribution volume of FDOPA (Vd).
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partitioning of FDOPA and OMFD is reduced from 4 
to 2 by the following assumptions: First, it is assumed 
that the blood-brain partitioning of FDOPA at equilib-
rium (Ve
D = K1
D/k2
D) is identical to that of OMFD (Ve
M 
= K1
M/k2
M). Second, this partitioning is assumed to be 
homogeneous throughout the brain. Finally, the magni-
tude of the unidirectional clearance of OMFD to that of 
FDOPA (q: K1
M/K1
D) is set at a fixed ratio, based upon 
early experiments (q = 1.5; Cumming and Gjedde 
1998). Although there remains some uncertainty about 
the true magnitude of q, the compartmental analysis is 
quite stable over a range of physiologically plausible q 
values (Leger and others 1998).
Conventional compartmental analysis using 
nonlinear least square optimization
The compartmental analysis of FDOPA metabolism 
in brain requires the dual arterial FDOPA and OMFD 
inputs mentioned above. Using the constrained approach, 
the nonlinear least square fitting is first obtained for the 
TAC in a reference region where the magnitude of k3
D is 
plausibly fixed at zero, thus yielding an estimate of the 
common partition volume FDOPA and OMFD, Ve, which 
has units mL g–1. This estimate is then used as a con-
straint to reduce the number of parameters to be esti-
mated in striatum to only two, namely K1
D and k3
D. 
Typical TACs in cerebellum and putamen are presented 
in Figure 3; results of fitting can be seen in our earlier 
publication (Kumakura and others 2005, Fig. 2).
The True Activity of AAADC 
in Living Brain
Compartmental analysis of FDOPA-PET studies gives 
estimates of the relative activity of AAADC (k3
D) gener-
ally close to 0.06 min–1 in striatum of healthy humans. 
According to Michaelis-Menten kinetics, the magnitude 
of k3
D should equal Vmax/KmVd (Reith and others 1994), 
predicting a magnitude of 1 min–1 on the basis of 
AAADC activity measured in homogenates of monkey 
striatum (Yee and others 2000) or rat striatum (Cumming 
and others 1988). How to account for the 15-fold dis-
crepancy between PET and enzymology results? Intrinsic 
factors in vivo might attenuate the AAADC activity with 
respect to FDOPA. On the other hand, typical estimates 
of k3
D based on biochemical analysis of metabolites in 
extracts from rat striatum (0.2 min–1) are closer to the 
predicted rate constant. Furthermore, the relatively low 
spatial resolution of PET results in substantial degrada-
tion of the measured brain TACs. Correcting FDOPA 
scans for the so-called effects of partial volume suggests 
that the “true” magnitude of k3
D in the striatum of nor-
mal humans is considerably higher than previously sus-
pected (Rousset and others 2000), falling in the range of 
the biochemical estimates.
Steady-State Methods for the 
Quantitation of FDOPA-PET Studies
All of the methods described above assume that [18F]
fluorodopamine, once formed, is irreversibly trapped 
within synaptic vesicles. However, plots of the linear 
graphical analysis, and also compartmental modeling 
results (Fig. 3), suggest that striatal radioactivity concen-
trations eventually fall under the calculated or extrapo-
lated curves. To correct for washout of trapped mass, an 
extended compartmental model must accommodate 1) 
the progressive catabolism of [18F]fluorodopamine, and 
2) the diffusion of acidic metabolites from brain. Adding 
the two kinetic parameters would entail an insupport-
able overspecification of the model. Therefore, these two 
processes have been lumped as a net washout rate con-
stant kloss (min
–1) (Huang and others 1991), in which 
[18F]fluorodopamine and its acidic metabolites are con-
sidered a single diffusible pool. This becomes essentially 
true for FDOPA-PET recordings longer than 1 hour, 
when an equilibrium develops between the vesicular and 
diffusible pools (Deep and others 1997a, 1997b).
The extended compartmental analysis does not give 
stable estimates of kloss when FDOPA recordings lasting 
only 2 hours are available (Danielsen and others 1999). 
However, stable estimates of the magnitude of k3
D cor-
rected for loss of the [18F]fluorodopamine metabolites 
(k3
D*) can be readily calculated in monkeys scanned for 4 
hours (Cumming and others 2001), during which time 
the washout of metabolites becomes quite substantial. 
Indeed, the magnitude of k3
D in monkey putamen is some 
40% less than is k3
D*, indicating that the irreversible trap-
ping model underestimates the AAADC activity because 
much of the [18F]fluorodopamine formed in brain has 
already been lost during the first hour of the PET study.
Relinearizing the Graphical Analysis
The deviating graphical analysis of prolonged FDOPA-
PET recordings can be relinearized by addition of an 
exponential term representing kloss (Holden and others 
1997; Cumming and others 2001; Sossi and others 
2001). Using this approach, the effect of COMT inhibi-
tion on kloss has been investigated; treatment with a 
COMT inhibitor acting in the central nervous system, 
the magnitude of kloss declined by 40% in monkey stria-
tum, whereas a peripherally acting COMT inhibitor was 
without effect on kloss (Holden and others 1997). This 
isolated finding suggests that brain COMT plays rather 
a greater role in the eventual catabolism of [18F]fluoro-
dopamine than has generally been appreciated, or may 
suggest a vulnerability of the model to altered FDOPA 
methylation in situ (k5
D; Cumming and Gjedde, 1998).
The ratio of the net tracer clearance to brain (Kin
app) 
to kloss has been called the effective distribution volume 
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of FDOPA in brain (EDV; mL g–1), corresponding to the 
steady-state FDOPA trapping capacity in brain (Sossi 
and others 2001). Whereas the magnitude of Kin
app had 
declined by only 27% in the putamen of patients with 
Parkinson’s disease, the magnitude of EDV had declined 
by 65% (Sossi and others 2004). Thus, the steady-state 
analysis is a more sensitive indicator of nigrostriatal 
degeneration, but requires 4-hour-long recordings. 
Therefore, an alternate method has been developed to 
estimate steady-state FDOPA kinetics using recordings 
lasting a more tolerable 2 hours (Kumakura and others 
2005, 2006). In this approach, the constrained compart-
mental model is first fitted to the reference tissue TAC, 
to calculate the separate FDOPA and OMFD TACs. 
Given that the OMFD concentration is nearly uniform in 
the brain, the OMFD TAC is then subtracted frame-by-
frame from the entire volume of the dynamic PET scan. 
This subtraction isolates the brain radioactivity due to 
FDOPA, [18F]fluorodopamine, and the acid metabolites, 
while avoiding the oversubtraction of FDOPA when 
the entire tissue radioactivity (OMFD and FDOPA) is 
subtracted, as in the conventional graphical analysis. 
Using the “mathematically cleaned” FDOPA recordings, 
we then calculate in each region of interest the magni-
tudes of the intrinsic FDOPA clearance (K) and kloss. 
The several estimates of the magnitude of kloss (Table 2) 
predict a half-life for brain [18F]fluorodopamine of 
approximately 2 hours in healthy striatum, similar to that 
seen in biochemical assays of dopamine turnover.
Optimization Using Multilinear 
Solution for kloss and EDV 
Our first attempts to measure kloss and EDV
 using 
mathematical subtraction of OMFD were based on 
nonlinear fitting of the resultant uptake curves 
(Kumakura and others 2005). However, our nonlinear 
methods involving cost-function optimization tended to 
fail in voxelwise parameter estimation. To address this 
problem, we developed a robust linear approach for 
FDOPA steady-state parametric mapping for the calcu-
lation of steady-state parameters in terms of the calcu-
lated FDOPA arterial input (Cp(t)) and the total mass 
of the tracer in brain, M(t). We expressed the model as 
a multilinear equation,
Z t
0
MðtÞdt= fEDV + ðVf +V0Þg
Z t
0
CpðtÞdt−
MðtÞ
kloss
+ Vf +V0
kloss
CpðtÞ
 
where the distribution volume of unmetabolized 
FDOPA in brain tissue (Vf) approaches a constant, K1/
(k2+k3), at some 20 minutes after FDOPA injection, 
and given an effective plasma volume in brain (V0), 
which should be close to 5% (Kumakura and others 
2006). The regression process enables calculation of 
the magnitudes of the three coefficients (macroparam-
eters) on the right hand side. Of these, the term {EDV 
+ (Vf + V0)}, equal to the total distribution volume 
(Vd), is the most reliable and robust parameter, and is 
the optimal term for parametric mapping based on 
2-hour FDOPA-PET recordings (Kumakura and others 
2008). This newly formulated “inlet-and-outlet” model 
(Fig. 2C) representing “internal irreversible kinetics 
contained in the global reversible kinetics” is clearly 
distinct from the conventional PET kinetic models 
(i.e., FDG or receptor ligands). Our novel modeling 
approach, predicated upon precise subtraction of brain 
OMFD contamination, allows the estimation of dopa-
mine storage capacity (expressed as Vd) even in regions 
of sparse dopamine innervation (Kumakura and others 
2008; Kienast and others 2008).
Multiple Fates for FDOPA in Brain 
and the Pharmacological Modulation 
of AAADC Activity
DOPA in brain has several possible fates, such that the 
activity of AAADC determines the “branching ratio” for 
the DOPA pathway. It follows that altering AAADC 
activity must change the fraction of DOPA proceeding 
to dopamine synthesis, rather than disposal by other 
pathways. This prediction has been tested in a number 
of pharmacological challenge studies with [3H]DOPA in 
living rats. Results of these studies have consistently 
suggested modulation of striatal AAADC activity via 
presynaptic autoreceptors (see, for example, Cumming 
and others 1995b).
Based on the results of [3H]DOPA studies men-
tioned above, autoreceptor modulation of AAADC activ-
ity has been tested in PET paradigms. Challenge with a 
typical antipsychotic medication acutely increased the 
FDOPA influx (Kin
app) in the putamen of healthy volun-
teers (Vernaleken and others 2006), suggesting activa-
tion of dopamine synthesis after autoreceptor blockade. 
In another such study, treatment of volunteers with an 
atypical antipsychotic failed to increase the striatal 
influx of FMT (Mamo and others 2004). This discrep-
ancy may be related to the uncertain metabolic fate of 
FMT, or it may simply be that FMT uptake is prone to 
a ceiling effect, if its trapping in healthy striatum is 
already so efficient that any further increase approaches 
the limit in influx imposed by the clearance across the 
blood-brain barrier (K1
D). In another FDOPA-PET study, 
subchronic treatment with haloperidol decreased the 
magnitude of k3
D in patients with schizophrenia, consis-
tent with down-regulation of dopamine synthesis 
(Grunder and others 2003). This latter finding was inter-
preted to reveal the onset of depolarization block, a 
putative mechanism for the 3-week delay in full clinical 
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response to antipsychotic treatment: if so, this would be 
the only evidence for the occurrence of depolarization 
block in the human brain.
Age-Related Changes Measured 
by FDOPA-PET
Cell counting studies generally have shown a 7% to 10% 
decline in the number of dopamine neurons of the sub-
stantia nigra with each decade of human life. Despite 
this precipitous decline in cell number, the activity of 
AAADC from postmortem brain was only 27% reduced 
in the caudate nucleus of elderly human subjects and 
was unchanged in the putamen (Kish and others 1995). 
Thus, compensatory changes may occur in the aging 
substantia nigra such that AAADC activity is preserved. 
Indeed, the great preponderance of FDOPA-PET stud-
ies have shown preserved tracer uptake with normal 
aging (Cumming and Gjedde 1998; Fig. 4). Similarly, 
there was only a trend toward declining FDOPA k3
S in 
aged monkeys (Doudet and others 2006). However, 
numerous model-based factors and biases may underlie 
the absent age-related changes in FDOPA kinetics. 
Using methods described above, we have found that the 
conventional calculation of Kin
app conceals an underlying 
decline with age in the magnitude of the inherent net 
blood-brain clearance. Parametric maps of FDOPA influx 
based upon a more physiologically valid subtraction of 
the OMFD curve (Kumakura and others 2005) revealed, 
in fact, a substantial decline with normal aging, which 
could not be detected in the corresponding k3
s and Kin
app 
maps. However, the net FDOPA influx reveals the dop-
amine synthesis capacity, assuming irreversible trapping 
of the tracer. The steady-state kinetic analysis described 
above revealed the occurrence of a substantial increase 
with age in the magnitude of kloss, the washout rate for 
[18F]fluorodopamine formed in striatum. Thus, dop-
amine synthesis was normal, but the retention of dop-
amine was impaired as a function of age. The index of 
vesicular storage (Vd), including these two terms, declined 
by 10% with each decade of healthy aging (Kumakura 
and others 2008), predicting that healthy aging would 
proceed to a condition of parkinsonism for otherwise 
healthy centenarians (Fig. 4). The FDOPA Kin
app was 
greater in the caudate nucleus of women than in age-
matched men (Laakso and others 2002), a finding that 
may have bearing on the slightly greater incidence of 
Parkinson’s disease in men.
Acquired Parkinsonism 
and Idiopathic Parkinson’s Disease
The relationship between FDOPA utilization and sur-
vival of dopamine neurons is best documented with the 
MPTP model of acquired parkinsonism in experimen-
tal animals. Here, PET results can be compared with 
postmortem histological analysis. Impaired FDOPA 
uptake in striatum of MPTP-poisoned monkeys was 
associated with atrophy of the remaining dopamine 
neurons in the substantia nigra (Pate and others 1993). 
Stereological cell counting showed that 200,000 dop-
amine neurons in the substantia nigra of healthy 
baboons supported an FDOPA k3
S of 0.007 min–1 in the 
striatum. In severely MPTP-poisoned baboons, there 
remained only 67,000 dopamine neurons, which 
imparted an FDOPA k3
S of only 0.001 min–1 (Poyot and 
others 2001). In monkeys with less severe MPTP-
poisoning, reduced FDOPA utilization correlated better 
with striatal dopamine concentration measured post-
mortem (Yee and others 2001), and with striatal activity 
of AAADC in vitro (Yee and others 2000), than with 
numerical loss of dopamine neurons. Relative preserva-
tion of FDOPA k3
S as a function of the severity of idio-
pathic Parkinson’s disease suggests the occurrence of 
compensatory up-regulation of AAADC in residual 
dopamine terminals (Lee and others 2000). Indeed, the 
“nonlinearity” of FDOPA utilization has been noted 
earlier (Barrio and others 1997).
FMT-PET followed by postmortem histology in 
MPTP-poisoned monkeys revealed general agreement 
between the pattern of reduced tracer influx and the 
topography of remaining dopamine neurons (Oiwa and 
others 2003). In a study of xenografting in pigs with 
MPTP-induced parkinsonism, some functional recov-
ery and improved FDOPA utilization was obtained in 
association with the grafting of approximately 100,000 
dopamine neurons surviving ectopically in the dop-
amine-depleted striatum (Dall and others 2002). In a 
group of five patients with neurodegenerative disease, 
cell counts in the substantial nigra correlated with 
results of earlier FDOPA-PET examinations (Snow 
and others 1993); this seems to be the only instance of 
follow-up histological examination in human FDOPA 
studies.
In patients with early hemiparkinsonism, the FDOPA 
utilization was more reduced in the striatum contralat-
eral to the motor symptoms, suggesting a threshold for 
decompensation (Morrish and others 1995). The rate of 
progression of Parkinson’s disease has been investigated 
in a number of longitudinal PET studies. Thus, the 
annual declines of FDOPA k3
s were 4% in the caudate 
and 6% in the putamen (Hilker and others 2005), or 6% 
in the caudate and 10% in the putamen of patients with 
Parkinson’s disease, versus less than 1% in healthy aged 
subjects (Nurmi and others 2001). In the REAL-PET 
study, the magnitude of k3
s in the putamen declined by 
6.5% per year in patients with Parkinson’s disease treated 
with ropinerole, versus 10% per year in patients treated 
with DOPA (Whone and others 2003), which may reveal 
a neuroprotective effect of direct dopamine agonists.
The first reductions in FDOPA utilization of early 
Parkinson’s disease are noted in the dorsal putamen; 
follow-up at 2 years later shows a further decline in the 
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dorsal putamen, along with additional loss in other 
regions of the striatum (Bruck and others 2006; Ishiwata 
and others 2007). Even in advanced Parkinson’s dis-
ease, the FDOPA influx was less impaired in the cau-
date nucleus (-45%) than in the putamen (–64%; 
Broussolle and others 1999). Elevated FDOPA utiliza-
tion in the frontal cortex has been described in PET 
studies of early Parkinson’s disease (Bruck and others 
2005; Rakshi and others 1999), more notably in women 
than in men (Kaasinen and others 2001b).
Other Clinical FDOPA Studies
Increased FDOPA Kin
app in the caudate of unmedicated 
patients with schizophrenia was an early finding in the 
history of quantitative FDOPA studies (Reith and oth-
ers 1994). This finding has since been replicated in 
several independent studies with FDOPA (Hietala and 
others 1999), with notably large increases present in the 
ventral striatum (McGowan and others 2004). In stud-
ies with β-[11C]DOPA, there was increased net influx 
throughout the striatum, and also the medial prefrontal 
cortex (Lindstrom and others 1999), a finding that was 
normalized after treatment with antipsychotic drugs 
(Gefvert and others 2003). In an fMRI study of schizo-
phrenia, the increased FDOPA influx to the striatum 
correlated with reduced BOLD signal changes in the 
prefrontal cortex during performance of a cognitive 
task (Meyer-Lindenberg and others 2002), suggesting a 
link between abnormal physiology of associated corti-
cal and subcortical structures. FDOPA influx was also 
increased in the striatum of first-degree relatives of 
patients with schizophrenia (Huttunen and others 
2008), suggesting that an overactive dopamine system 
may be a risk factor or trait marker for developing psy-
chosis. Steady-state kinetic analysis showed the 
expected increase in FDOPA utilization and an even 
greater increase in [18F]fluorodopamine washout (kloss) 
in patients with schizophrenia (Kumakura and others 
2007). The net effect of these two increases was a 
reduced FDOPA Vd, a circumstance we described as 
“poverty in the midst of plenty” (Fig. 4). In a single 
FDOPA study of untreated patients with nonpsychotic 
mania, influx was normal, but was reduced by treatment 
with a mood stabilizer (Yatham and others 2002).
The FDOPA Kin
app was 30% greater in the caudate 
nucleus of smokers than in nonsmoking control subjects 
(Salokangas and others 2000). It remains uncertain if 
this reflects a pharmacological action of tobacco smoke, 
or an underlying personality trait associated predisposing 
for smoking. However, acute treatment with nicotine 
increased the utilization of β-[11C]DOPA in the striatum 
of awake monkeys (Tsukada and others 2005). Thus, it 
is interesting that the magnitude of FDOPA Kin
app was 
entirely normal in the striatum of alcoholics, but none-
theless correlated inversely with individual scores for 
craving, a predictor for relapse (Heinz and others 
2005). It is as if the pathological trait expresses itself 
through the (essentially normal) dopamine system at 
hand. FDOPA-PET could be used to identify a subset 
of alcoholic patients potentially benefiting from treat-
ment with DOPA or direct dopamine agonists.
Personality and Cognition
Psychological test batteries can score distinct trait and 
propensities, and their relationship results of PET stud-
ies. The Tridimensional Personality Questionnaire of 
Cloninger provides scores on three distinct axes, known 
as reward dependence, novelty seeking, and harm 
avoidance, to which is sometimes added the additional 
dimension of persistence. In an FDOPA-PET study of 
patients with Parkinson’s disease, FDOPA uptake in 
the caudate correlated positively with the novelty seek-
ing (Menza and others 1995) and harm-avoidance 
scores (Kaasinen and others 2001a). These results may 
support the usual clinical observation that patients 
with Parkinson’s disease tend to be withdrawn and lack-
ing in adventurousness. However, there was no relation-
ship between FDOPA influx and harm avoidance in 
healthy elderly control subjects (Kaasinen and others 
2002). High scores in ratings of anxiety and aggressive-
ness, which was assessed with another self-report ques-
tionnaire, the Karolinska Scales of Personality, correlated 
with low influx of FDOPA in the caudate nucleus of 
normal young subjects (Laakso and others 2003).
In an FDOPA study employing principle compo-
nent analysis, impaired FDOPA utilization segregated 
with motor symptoms, but not cognitive function and 
mood of Parkinson’s patients without diagnosis of major 
depression (Broussolle and others 1999). This would 
seem to exclude important contributions of nigrostriatal 
degeneration per se to declining cognitive function and 
mood in patients with Parkinson’s disease. However, 
others have reported that reduced FDOPA influx spe-
cifically to caudate predicted poor performance of the 
Stroop interference task, a test of executive function of 
the frontal lobes (Rinne and others 2000). In a subse-
quent FDOPA study of cognition in patients with 
Parkinson’s disease, there was a very high correlation 
between impaired FDOPA uptake in the caudate nucleus 
and putamen with scores in a item known as “concen-
tration difficulties” (Koerts and others 2007). However, 
this finding need not necessarily indicate a causal link, 
inasmuch as the decline in striatum FDOPA metabo-
lism might be a surrogate marker for other pathologies 
impairing cognitive function.
In healthy subjects, the score in the performance of 
the Stroop test correlated with FDOPA Kin
app through-
out the striatum of a group of healthy volunteers 
(Vernaleken and others 2007), a finding that was cor-
roborated in an FMT-PET study showing a positive 
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correlation between striatal tracer uptake and digit span 
of healthy subjects (Cools and others 2008). These find-
ings stand in contrast to the reported relationship 
between prefrontal BOLD signal and FDOPA influx in 
patients with schizophrenia, cited above, in which 
impaired prefrontal activity predicted especially elevated 
FDOPA influx. In another dual-modality imaging study 
of normal subjects, the magnitude of activation of the 
fMRI BOLD signal evoked in frontal cortex by emotion-
ally positive visual stimuli correlated with FDOPA Kin
app 
in the ventral striatum (Siessmeier and others 2006). 
More recently, the “inlet-outlet” model has been used to 
investigate the relationship between normal cognition 
and FDOPA metabolism (Vernaleken and others 2008). 
Within the healthy group, some subjects were character-
ized by a volatile dopamine system, with low FDOPA 
influx and rapid turnover of [18F]fluorodopamine, whereas 
others had a seemingly indolent system, with high 
FDOPA influx and low turnover. Only the former sub-
group experienced improved cognition under treatment 
with haloperidol, suggesting that individual differences 
in the dynamic range of the responsiveness of dopamine 
systems may be a factor related to “cognitive style.”
This last observation introduces the concept of 
FDOPA “parameter space” defined by the twin axes of 
inherent to the steady-state model. Here, the capacity to 
synthesize dopamine, as revealed by the net influx of 
tracer to brain (K or Kin
app), is functionally distinct from 
the rate of dopamine turnover, which is related to kloss. 
Normal individuals can occupy a certain domain of these 
two parameters, which changes as a function of normal 
aging. To some extent, one’s cognitive performance, 
motor behavior, and vulnerability to disease may be influ-
enced by the position in this parameter space, while still 
remaining within the normal limits for a given age group. 
However, patients with diseases such as schizophrenia or 
Parkinson’s disease clearly occupy distinct domains of 
FDOPA parameter space, as depicted in Figure 5.
In conclusion, the methodologically convenient esti-
mates of FDOPA net influx are sensitive and useful 
indicators of several neuropsychiatric disorders. However, 
the more sophisticated steady-state analysis can reveal 
deeper insights into the life of the dopamine neurons, 
and can reveal abnormalities not evident in the simple 
measures of influx, which assume irreversible trapping 
of [18F]fluorodopamine formed in living striatum. As 
discussed above, FDOPA-PET has been available for 
more than 25 years. However, the refinement of kinetic 
modeling has been a continuous process, leading to ever 
new insights about brain dopamine.
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